<DOC>
	<DOC>NCT01321723</DOC>
	<brief_summary>This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.</brief_summary>
	<brief_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women</brief_title>
	<detailed_description>The choice of a 24-week treatment period was based on published studies of PTH which demonstrate its potential to produce a statistically significant increase in BMD in patients with postmenopausal osteoporosis within that observation period.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Healthy postmenopausal women (4580 years old) with a diagnosis of osteoporosis Use of estrogen or hormone replacement therapy Use of bisphosphonates, strontium ranelate or denosumab Use of parathyroid analogues or other bone metabolic agents Medical conditions which might alter bone metabolism Any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia Impairment of thyroid function</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Diseases, Metabolic</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
</DOC>